FilingSEC EDGAR8-K
CAMP4 Therapeutics Announces Phase 1/2 ASCEND Clinical Trial Plan for CMP-002
· SEC accepted
StagePhase 1/2
Filing content
The company announced the Phase 1/2 ASCEND clinical trial plan for CMP-002 in SYNGAP1-related disorder, targeting the first patient dose by the end of 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…